Background--Outcomes data among patients with heart failure (HF) with reduced ejection fraction treated with sacubitril/ valsartan (SAC/VAL) are largely limited to clinical trial results. We compared hospitalization and healthcare costs among real-world patients with HF with reduced ejection fraction treated with SAC/VAL versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker (ACEI/ARB).
H eart failure (HF) is a major cause of morbidity and mortality; as recently as 2014, %900 000 hospital discharges for HF occurred in the United States. 1 The cost associated with HF-estimated at $31 billion in 2012-is forecasted to increase to $70 billion by 2030, driven by an aging population and epidemiological factors such as obesity, hypertension, diabetes mellitus, and coronary artery disease. 2, 3 Although HF is poised to remain a heavy burden on the US healthcare system for years to come, in recent decades pharmacological therapy enhancements have reduced morbidity and mortality among patients with HF with reduced ejection fraction (HFrEF). 4 Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) improve clinical outcomes in HFrEF 4 and were the mainstays of HFrEF renin-angiotensin system blockade therapy until 2015, when sacubitril/valsartan (SAC/VAL), a combination neprilysin inhibitor and ARB, was approved by the US Food and Drug Administration. SAC/VAL is used in patients with chronic HFrEF and New York Heart Association functional class II to IV symptoms. Approval of SAC/VAL was based largely on the strength of results from the PARADIGM-HF
(Prospective Comparison of Angiotensin Receptor-Neprilysin
Inhibitor with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, in which SAC/VAL reduced the risk of cardiovascular death and first HF hospitalization among patients with HFrEF by 20% compared with the ACEI, enalapril. 5, 6 Reducing hospitalization risk is critical, given that HF hospitalization has been associated with higher 30-to 60-day mortality and readmission rates 7 and accounts for the majority of costs attributable to HF in the United States. 8 Although PARADIGM-HF illustrated superior efficacy of SAC/VAL compared with enalapril in a clinical trial setting, 6 real-world data regarding outcomes associated with SAC/VAL use-including potential economic benefit-are limited. This study was conducted to compare hospitalization and healthcare costs among stable patients with HFrEF treated with SAC/VAL versus an ACEI or ARB in clinical practice.
Methods Study Design and Data Sources
Research materials, data, and analytical methods will not be made available to other researchers for purposes of replicating analysis procedures or reproducing study results.
This retrospective study was conducted using administrative claims data from October 1, 2014 through September 30, 2016 from the Optum Research Database (ORD) with merged mortality data from the US Social Security Administration public death master file. The ORD is a large, populationrepresentative database containing de-identified medical and pharmacy claims data and linked enrollment information for individuals enrolled in US commercial and Medicare Advantage health plans. Medical claims included diagnosis and procedure codes from the International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM); Current Procedural Terminology or Healthcare Common Procedure Coding System codes; site of service codes; paid amounts; and other information. Pharmacy claims included drug name, dosage form, drug strength, fill date, number of days' supply, and financial information for health plan-provided outpatient pharmacy services. Because no identifiable protected health information was accessed during this study, institutional review board approval or waiver of authorization was not required.
Patient Identification and Cohort Assignment
The study included patients with at least 1 pharmacy claim for SAC/VAL, ACEI, or ARB from October 1, 2015 through June 30, 2016 (identification period). Adults with a claim for SAC/ VAL during the identification period and no previous claims for SAC/VAL were assigned to the SAC/VAL cohort, and those with a claim for ACEI or ARB during the identification period and no claims for SAC/VAL from July 7, 2015 (market approval) through September 30, 2016 (end of the study period) were assigned to the ACEI/ARB cohort. The date of the first claim for the index therapy was defined as the index date. Continuous enrollment in the health plan with both medical and pharmacy coverage was required during the 12 months preceding the index date (preindex period) and for a minimum 3-month postindex period starting on the index date and ending on the earliest of the following: end of the study period, health plan disenrollment, or death.
Included patients were required to have claims evidence of HFrEF and a stable clinical status. Criteria for claims evidence of HFrEF and stable status are given in Figure 1 . Patients were also required to be aged ≥18 years (and <65 years if they had a commercial health plan) and to have no missing demographic data. Finally, in order to control for possible early differences in days' supply of the index therapy (eg, 30-versus 90-day supply) between cohorts, only patients with proportion of days covered ≥0.80 in the first 3 months of the postindex period were retained in the study sample.
To account for potential selection bias, cohorts were 1:1 propensity-score matched on selected demographics and preindex patient characteristics (see Table 1 ), including exact matching on health plan type (commercial or Medicare
Clinical Perspective
What Is New?
• In real-world clinical practice settings, patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan were less likely to be hospitalized than patients treated with an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker after controlling for patient demographics, comorbid conditions, and other factors.
• Patients treated with sacubitril/valsartan also had lower hospitalization costs and total all-cause healthcare costs than those treated with angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker.
What Are the Clinical Implications?
• Cost is often implicated as a barrier to use of novel pharmacological therapy for heart failure with reduced ejection fraction; however, in our real-world analysis, increased pharmacy costs for sacubitril/valsartan -treated patients were mitigated by lower medical costs.
• Healthcare providers need to consider clinical benefit and total costs in addition to drug costs when making treatment decisions.
Advantage). For each patient in the SAC/VAL cohort, a patient in the ACEI/ARB cohort with the closest propensity score within a caliper of 0.20 of the SD of the estimated logit was selected. Unmatched patients were excluded from the analysis.
Patient Characteristics and Outcomes
Patient characteristics included demographic information (age, sex, health plan type, and geographical region); duration of the postindex period; preindex Quan-Charlson comorbidity score; 10 selected preindex comorbid conditions, signs and symptoms (based on ICD-9-CM or ICD-10-CM diagnosis codes), preindex HF-related outpatient pharmacotherapy (ACEI/ARB, evidence-based beta blocker, mineralocorticoid receptor agonist, loop diuretic, thiazide diuretic, and digoxin); selected preindex other outpatient pharmacotherapy (anticoagulant, antiplatelet agent, nondihydropyridine calcium-channel blocker, dihydropyridine calcium-channel blocker, lipidaltering medication, vasodilator, insulin, or noninsulin hypoglycemic agent); number of preindex HF-related guideline therapies (ACEI/ARB, evidence-based beta blocker, mineralocorticoid receptor agonist, isosorbide dinitrate+hydralazine, digoxin, and ivabradine); preindex cardiac resynchronization , preindex HF-related outpatient pharmacotherapy (ACEI/ARB, evidence-based beta blocker, mineralocorticoid receptor agonist, loop diuretic, thiazide diuretic, and digoxin), selected preindex other outpatient pharmacotherapy (anticoagulant, antiplatelet agent, nondihydropyridine calcium-channel blocker, dihydropyridine calcium-channel blocker, lipid-altering medication, vasodilator, insulin, and noninsulin hypoglycemic agent), preindex revascularization, preindex all-cause medical and pharmacy costs (health plan-dependent quintiles), and encounter with cardiologist in the month preindex. Each preindex outpatient pharmacotherapy was calculated as total days' supply. † Match performed using categorical version. ‡ Identified using ICD-9-CM and ICD-10-CM diagnosis codes. § Guideline-recommended medical therapies included ACEI/ARB, evidence-based beta blocker, mineralocorticoid receptor agonist, isosorbide dinitrate+hydralazine, digoxin, and ivabradine. Patient-paid amounts were also calculated separately. Allcause healthcare costs were reported as total costs and for subcategories of medical, hospital, and outpatient pharmacy costs.
Statistical Analysis
The pre-and postmatch balances of patient characteristics between cohorts were evaluated using standardized mean differences (SMDs; by convention, values ≥10% indicated meaningful imbalance). 12 Postindex hospitalization (PPPM counts) and healthcare costs between matched cohorts were compared using robust variance estimation. Time to first postindex hospitalization (HF and all-cause) was modeled using Kaplan-Meier failure probability estimates and multivariable Cox proportional hazards models. Postindex all-cause healthcare costs were modeled using a multivariable generalized linear model with gamma distribution and log link. In addition to cohort, adjustment variables for multivariable modeling included age and health plan type interaction, sex, selected (a priori) preindex chronic comorbid conditions, selected (a priori) preindex signs and symptoms, number of preindex guideline therapies, preindex cardiac resynchronization therapy/implantable cardioverter defibrillator, preindex revascularization, preindex HF hospitalization, preindex all-cause medical costs, and preindex all-cause outpatient pharmacy costs. Because the precision of signs/symptoms identified from ICD-9/10-CM codes may vary, sensitivity analyses in which preindex signs and symptoms were excluded from the multivariable models were also performed. Statistical analysis was performed using SAS software (version 9.4; SAS Institute Inc, Cary, NC). P<0.05 was considered statistically significant.
Results

Study Sample
Among patients who initiated 1 of the index therapies during the identification period, the remaining selection criteria were satisfied by 287 in the SAC/VAL cohort and 22 469 in the ACEI/ARB cohort ( Figure 2 Index date: date of first pharmacy claim for SAC/VAL or ACEI/ARB. ACEI/ARB indicates angiotensinconverting enzyme inhibitor or angiotensin-receptor blocker; CRT/ICD, cardiac resynchronization therapy/ implantable cardioverter-defibrillator; HFrEF, heart failure with reduced ejection fraction; MI, myocardial infarction; PDC, proportion of days covered; SAC/VAL, sacubitril/valsartan. *Criteria for claims evidence of HF and stable status are provided in Figure 1 . † Variables used in propensity score matching are provided in Table 1 The impact on patient-paid costs was similar to that observed for overall costs. Compared with ACEI/ARBtreated patients, those treated with SAC/VAL had lower postindex PPPM patient-paid HF hospital costs (P=0.023), all-cause total costs (P=0.023), all-cause medical costs (P<0.001), and all-cause hospital costs (P<0.001), but higher postindex PPPM all-cause outpatient pharmacy costs (P<0.001; Figure 4 ).
Postindex Hospitalization
Discussion
In this real-world analysis, patients with HFrEF treated with SAC/VAL in clinical practice were less likely to be hospitalized and incurred lower total healthcare costs than those treated with ACEI/ARB. Our results provide an important complement to those of PARADIGM-HF, in which SAC/VAL was superior to enalapril for reducing cardiovascular death and first HF hospitalization in a clinical trial setting. 6 Real-world data regarding longitudinal health economic outcomes among patients with HFrEF who were treated with SAC/VAL have been reported in only 1 other article to date, a single-arm report by Antol et al. 13 The substantial reduction in hospitalization observed in our study's SAC/VAL cohort was congruent with findings from the Antol et al study, which involved enrollees in health plans managed by Humana (primarily Medicare Advantage). After initiating SAC/VAL, patients had a decrease in 3-month all-cause hospitalization, from 27.5% to 17.0%. 13 Hospitalization is an important outcome in HFrEF; it is widespread, 14 and patients who are hospitalized are highly likely to be readmitted. 8, 15 In a 2017 analysis, more than 40%
of Medicare beneficiaries hospitalized for HF were readmitted within 90 days. 15 Given that hospitalization is a robust predictor of increased mortality in the HFrEF population, 7 reduction of inpatient admissions is essential to improving patient morbidity and mortality outcomes. In this study, total postindex HF hospital costs and allcause total healthcare costs were lower for patients treated with SAC/VAL versus ACEI/ARB. Despite strong evidence of superior efficacy, adoption of SAC/VAL in clinical practice after US market approval has been relatively slow, with reports ranging from 2% 16 to 13% 17 of patients with HFrEF.
Cost has often been implicated as a barrier to use of novel pharmacological therapy, because both health plan-and patient-paid costs for new drugs are considerably higher than those for established HFrEF guideline therapies. 16, 18, 19 In 2016, the estimated monthly retail cost of treatment with SAC/VAL was $425 compared with $9 and $25 for lisinopril and enalapril, respectively, 19 and in a retrospective analysis using 2015-2016 data from the OptumLabs Data Warehouse, patient-paid monthly costs for SAC/VAL remained high-a mean of $71 compared with $2 to $3 for lisinopril, losartan, carvedilol, and spironolactone-despite the majority of monthly costs being covered by payers. 16 Our findings offer new evidence that SAC/VAL provides value in terms of healthcare costs (HF hospital, all-cause total, all-cause medical, and all-cause hospital). Perceptions surrounding drug cost should be balanced with clinical and total cost benefits. Similar to other analyses of real-world data for SAC/ VAL, our results reflect an early view (the first 15 months after US Food and Drug Administration approval) of patient access to this therapy. As additional evidence of clinical practice outcomes becomes available and SAC/VAL is increasingly accepted by the healthcare community, its accessibility and affordability may change markedly. In our analysis, and congruent with existing data, both combined and patient-paid outpatient pharmacy costs were higher for SAC/VAL compared with ACEI/ARB. Higher drug costs were offset by reduced monthly medical costs; in particular, hospital costs and total healthcare costs were lower in the SAC/VAL cohort. Our real-world results provide further evidence that the economic burden of HF is dominated by inpatient costs. In 1 report, inpatient costs accounted for as much as 62% of total healthcare costs. 15 Economic modeling analyses using data from PARADIGM-HF consistently indicated that treating HFrEF with SAC/VAL compared with enalapril would be cost-effective from a US payer perspective. [20] [21] [22] [23] The present report expands on current knowledge by examining cost from a patient perspective. Interestingly, our finding that total healthcare costs were lower for SAC/VAL initiators contrasts with findings from modeling analyses, in which researchers suggested that increased quality-adjusted life-years associated with SAC/ VAL use among patients with HFrEF would come with higher healthcare costs. [20] [21] [22] [23] Possible explanations for this discrepancy include differences in event rates between our patient sample and the PARADIGM-HF study sample, as well as our use of actual paid amounts rather than modeled cost data. Our results contribute to the body of literature and can be utilized to help make future cost-effectiveness analyses more reflective of real-world patient outcomes. 
Study Limitations
Our findings should be interpreted in light of several limitations. Because this was a retrospective observational study, causal relationships cannot be inferred between the outcomes of interest and treatment with SAC/VAL or ACEI/ ARB. Furthermore, the potential impact of concomitant HFrelated therapies was not examined, and other unmeasured variables, such as drug dosage, patient socioeconomic status, or provider performance metrics, may have also affected the results. This study was conducted in a US managed-care sample, and the mean length of the postindex period was 6 months. Results may not be generalizable to other populations, such as patients who are uninsured or on fee-forservice healthcare plans, and may be most relevant in the short-term period following SAC/VAL (versus ACEI/ARB) initiation. Patients in the cohorts were matched at a 1:1 ratio, which limited the precision of estimators; however, a 1:1 ratio was chosen to reduce bias in estimators to the greatest possible extent. In addition, some small betweencohort differences in several preindex patient characteristics remained after matching. Although the list of match variables was extensive, it is also possible that there were betweencohort imbalances in disease severity that were not evident in the observed patient characteristics, particularly given that the diagnosis codes used to identify signs and symptoms can be imprecise and do not capture stability or severity, and patients with more-persistent symptoms may have been more likely to initiate SAC/VAL. Because this study used claims data, we recognize inherent limitations; most important, pharmacy claims reflected medication fills, not over-thecounter drug use, physician-provided samples, fills not processed through the primary insurer (eg, medications available through low-cost generic programs), or medications prescribed but not filled. In addition, presence of a diagnosis code on a medical claim does not assure the presence of disease, given that diagnoses may be coded incorrectly or included as rule-out criteria. Conversely, identification of conditions and signs and symptoms based on diagnosis codes requires that they were actually coded. Some information is not available in claims data, such as New York Heart Association functional class, ejection fraction percentage, blood pressure, and results from testing of serum electrolytes and biomarkers (eg, potassium, renal function markers, and N-terminal pro-B-type natriuretic peptide). Finally, a proxy algorithm was used to help identify patients with HFrEF.
Conclusion
Among patients with HFrEF, treatment with SAC/VAL in clinical practice was associated with lower short-term postindex hospitalization risk and total healthcare costs compared with treatment with ACEI/ARB. Increased pharmacy costs for SAC/VAL-treated patients were mitigated by lower medical costs, including HF and all-cause hospital costs. These findings underscore the need to consider clinical benefit and total costs in addition to drug costs when making treatment decisions. Treatment of real-world patients with SAC/VAL has the potential to improve clinical outcomes and reduce the economic burden of HFrEF.
